Synthesis and anti-hyperglycemic activity of hesperidin derivatives.
A series of hesperidin derivatives were prepared and identified by IR, (1)H NMR, and MS spectra. These compounds were evaluated in vitro and in vivo based on α-glucosidase inhibition, glucose consumption of HepG2 cells, and blood glucose level in streptozotocin-induced diabetic mice. The results revealed that all the compounds exhibited anti-hyperglycemic activities. The inhibition at 10(-3) M of compounds 3 and 7a on α-glucosidase were 55.02% and 53.34%, respectively, as compared to 54.80% by acarbose. Treated by compound 3 and the reference drug metformin, glucose consumption of HepG2 cell were 1.78 and 2.11 mM, respectively. After the streptozotocin-induced diabetic mice were oral administrated with compound 3 at 100 mg kg(-1) d(-1) for 10 days, the blood glucose level of 3 treated mice (13.23 mM, P<0.05) showed significant difference when compared to model control (23.03 mM). Thus, compound 3 exhibited promising anti-hyperglycemic activity.
College of Pharmaceutical Sciences, Southwest University, Chongqing 400716, PR China. zbs360@163.com
Baoshun
B
Zhang
Tingting
T
Chen
Zhu
Z
Chen
Mingxue
M
Wang
Dengyu
D
Zheng
Jinfeng
J
Wu
Xiaofei
X
Jiang
Xuegang
X
Li
D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy; D044950:Flavanones / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use; D065089:Glycoside Hydrolase Inhibitors; D056945:Hep G2 Cells; D006569:Hesperidin / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use; D051379:Mice; D013329:Structure-Activity Relationship; D000520:alpha-Glucosidases / Q000378:metabolism
D001786:Blood Glucose; D044950:Flavanones; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D006569:Hesperidin; D000520:alpha-Glucosidases